In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

VT-1129 is a novel fungal enzyme-specific Cyp51 inhibitor with potent cryptococcal activity. Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strategy against cryptococcal meningitis. VT-1129 plas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Wiederhold, Nathan P., Xu, Xin, Wang, Amy, Najvar, Laura K., Garvey, Edward P., Ottinger, Elizabeth A., Alimardanov, Asaf, Cradock, Jim, Behnke, Mark, Hoekstra, William J., Brand, Stephen R., Schotzinger, Robert J., Jaramillo, Rosie, Olivo, Marcos, Kirkpatrick, William R., Patterson, Thomas F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201077/
https://ncbi.nlm.nih.gov/pubmed/30104280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01315-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados